193 related articles for article (PubMed ID: 31028289)
1. Use of polymeric CXCR4 inhibitors as siRNA delivery vehicles for the treatment of acute myeloid leukemia.
Wang Y; Xie Y; Williams J; Hang Y; Richter L; Becker M; Amador C; Oupický D; Hyde RK
Cancer Gene Ther; 2020 Feb; 27(1-2):45-55. PubMed ID: 31028289
[TBL] [Abstract][Full Text] [Related]
2. Targeting CXCR4/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia.
Landry B; Gül-Uludağ H; Plianwong S; Kucharski C; Zak Z; Parmar MB; Kutsch O; Jiang H; Brandwein J; Uludağ H
J Control Release; 2016 Feb; 224():8-21. PubMed ID: 26742943
[TBL] [Abstract][Full Text] [Related]
3. Balancing polymer hydrophobicity for ligand presentation and siRNA delivery in dual function CXCR4 inhibiting polyplexes.
Wang Y; Li J; Chen Y; Oupický D
Biomater Sci; 2015 Jul; 3(7):1114-23. PubMed ID: 26146552
[TBL] [Abstract][Full Text] [Related]
4. Defining the in vivo characteristics of acute myeloid leukemia cells behavior by intravital imaging.
Duarte D; Amarteifio S; Ang H; Kong IY; Ruivo N; Pruessner G; Hawkins ED; Lo Celso C
Immunol Cell Biol; 2019 Feb; 97(2):229-235. PubMed ID: 30422351
[TBL] [Abstract][Full Text] [Related]
5. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.
Sison EA; McIntyre E; Magoon D; Brown P
Mol Cancer Res; 2013 Sep; 11(9):1004-16. PubMed ID: 23754844
[TBL] [Abstract][Full Text] [Related]
6. A non-viral nano-delivery system targeting epigenetic methyltransferase EZH2 for precise acute myeloid leukemia therapy.
Kaundal B; Kushwaha AC; Srivastava AK; Karmakar S; Choudhury SR
J Mater Chem B; 2020 Sep; 8(37):8658-8670. PubMed ID: 32844866
[TBL] [Abstract][Full Text] [Related]
7. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
[TBL] [Abstract][Full Text] [Related]
8. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy.
Cho BS; Zeng Z; Mu H; Wang Z; Konoplev S; McQueen T; Protopopova M; Cortes J; Marszalek JR; Peng SB; Ma W; Davis RE; Thornton DE; Andreeff M; Konopleva M
Blood; 2015 Jul; 126(2):222-32. PubMed ID: 26031918
[TBL] [Abstract][Full Text] [Related]
9. Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer.
Liu JY; Chiang T; Liu CH; Chern GG; Lin TT; Gao DY; Chen Y
Mol Ther; 2015 Nov; 23(11):1772-1782. PubMed ID: 26278330
[TBL] [Abstract][Full Text] [Related]
10. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.
Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM
Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632
[TBL] [Abstract][Full Text] [Related]
11. Polyplex-mediated inhibition of chemokine receptor CXCR4 and chromatin-remodeling enzyme NCOA3 impedes pancreatic cancer progression and metastasis.
Wang Y; Kumar S; Rachagani S; Sajja BR; Xie Y; Hang Y; Jain M; Li J; Boska MD; Batra SK; Oupický D
Biomaterials; 2016 Sep; 101():108-120. PubMed ID: 27267632
[TBL] [Abstract][Full Text] [Related]
12. Myeloid translocation gene CBFA2T3 directs a relapse gene program and determines patient-specific outcomes in AML.
Steinauer N; Guo C; Huang C; Wong M; Tu Y; Freter CE; Zhang J
Blood Adv; 2019 May; 3(9):1379-1393. PubMed ID: 31040112
[TBL] [Abstract][Full Text] [Related]
13. Development of functional poly(amido amine) CXCR4 antagonists with the ability to mobilize leukocytes and deliver nucleic acids.
Wang Y; Hazeldine ST; Li J; Oupický D
Adv Healthc Mater; 2015 Apr; 4(5):729-38. PubMed ID: 25491178
[TBL] [Abstract][Full Text] [Related]
14. Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib.
Dillmann F; Veldwijk MR; Laufs S; Sperandio M; Calandra G; Wenz F; Zeller J; Fruehauf S
Leuk Lymphoma; 2009 Oct; 50(10):1676-86. PubMed ID: 19657955
[TBL] [Abstract][Full Text] [Related]
15. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
[TBL] [Abstract][Full Text] [Related]
16. Cholesterol Modification Enhances Antimetastatic Activity and siRNA Delivery Efficacy of Poly(ethylenimine)-Based CXCR4 Antagonists.
Wu P; Luo X; Wu H; Yu F; Wang K; Sun M; Oupicky D
Macromol Biosci; 2018 Nov; 18(11):e1800234. PubMed ID: 30259651
[TBL] [Abstract][Full Text] [Related]
17. Role of CXCR4 in the pathogenesis of acute myeloid leukemia.
Peled A; Tavor S
Theranostics; 2013; 3(1):34-9. PubMed ID: 23382784
[TBL] [Abstract][Full Text] [Related]
18. Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4.
Pallarès V; Núñez Y; Sánchez-García L; Falgàs A; Serna N; Unzueta U; Gallardo A; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
J Control Release; 2021 Jul; 335():117-129. PubMed ID: 34004204
[TBL] [Abstract][Full Text] [Related]
19. CXCR4 Overexpression is a Poor Prognostic Factor in Pediatric Acute Myeloid Leukemia With Low Risk: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group.
Matsuo H; Nakamura N; Tomizawa D; Saito AM; Kiyokawa N; Horibe K; Nishinaka-Arai Y; Tokumasu M; Itoh H; Kamikubo Y; Nakayama H; Kinoshita A; Taga T; Tawa A; Taki T; Tanaka S; Adachi S
Pediatr Blood Cancer; 2016 Aug; 63(8):1394-9. PubMed ID: 27135782
[TBL] [Abstract][Full Text] [Related]
20. Cholangiocarcinoma therapy with nanoparticles that combine downregulation of MicroRNA-210 with inhibition of cancer cell invasiveness.
Xie Y; Wang Y; Li J; Hang Y; Jaramillo L; Wehrkamp CJ; Phillippi MA; Mohr AM; Chen Y; Talmon GA; Mott JL; Oupický D
Theranostics; 2018; 8(16):4305-4320. PubMed ID: 30214622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]